Zydus Life Q1: Strong Revenue Growth, But Profit Takes a Hit
Zydus Lifesciences reported a mixed set of numbers for Q1. While consolidated revenue from operations grew 22% YoY to ₹6,017 crore, net profit declined sharply by 36% to ₹909.8 crore.
The pressure was also visible on the operating side. EBITDA declined 8% to ₹1,629 crore, while EBITDA margin contracted to 24.1% from 31.8% in the same period last year. So, despite healthy topline growth, profitability and margins remained the key weak spots this quarter.
Looking deeper into the business, the consumer wellness segment was a major growth driver with revenue rising 67% to ₹1,439 crore. India formulations grew 20% to ₹1,896 crore, while international markets formulations jumped 34% to ₹744 crore. However, North America formulations revenue declined 3% to ₹3,098 crore.
One interesting point from management is that the branded portfolio now contributes more than 35% of revenue. Branded sales in the US contribute around 11% and could expand further with the upcoming launch of Saroglitazar.
For investors, the quarter shows two sides of Zydus: strong growth across several businesses, but significant pressure on margins and overall profitability. Going ahead, the key thing to watch will be whether revenue growth can translate into better EBITDA margins and earnings.
Learning Outcome: Revenue growth alone doesn't tell the complete story. Always compare sales growth with EBITDA margins and profit growth to understand the quality of a company's quarterly performance.